Related references
Note: Only part of the references are listed.Biosimilars of Biological Drug Therapies Regulatory, Clinical and Commercial Considerations
George Dranitsaris et al.
DRUGS (2011)
Fresh from the biologic pipeline-2010
Jim Kling
NATURE BIOTECHNOLOGY (2011)
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland
Alain Beck et al.
mAbs (2010)
Basic facts about biosimilars
Michal Nowicki
KIDNEY & BLOOD PRESSURE RESEARCH (2007)
Opinion - The FDA's assessment of follow-on protein products: a historical perspective
Janet Woodcock et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Importance of biologic follow-ons: experience with EPO
N Casadevall et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2005)
Rational design and engineering of therapeutic proteins
SA Marshall et al.
DRUG DISCOVERY TODAY (2003)
Share Paper
